---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000030"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-03-12T23:59:59+00:00"
generated_at: "2026-06-04T23:08:05.913042+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rallybio reports Q4 net loss $20.2M, cash $109.9M; workforce cut 45%, Phase 2 RLYB212 on track

## Summary
- Net loss Q4 2023 $20.2M ($0.50/sh); full year loss $74.6M ($1.84/sh).
- Cash, equivalents, marketable securities $109.9M at Dec 31, 2023; runway into mid-2026 after 45% workforce reduction.
- EMA protocol assistance feedback received for RLYB212; Phase 2 FNAIT study expected to start 2H 2024.
- RLYB116 Phase 1 multiple dose showed >93% free C5 reduction; manufacturing enhancements to enable higher doses.
- R&D expenses $53.5M (up 31% YoY); G&A $25.4M (down 7% YoY).

## SEC filing metadata
- accession: 0001739410-24-000030
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/0001739410-24-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/rlyb-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000030
- JSON: https://secwatch.observer/filing/0001739410-24-000030.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000030.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On March 12, 2024, Rallybio Corporation issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000030/0001739410-24-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.